The Story Of India’s Economic Pushback Against China
Local Manufacturing Of 35 APIs Under PLI Scheme Underway As India Seeks Atmanirbharta In Pharma Sector By Reducing Imports From China
Why Are Brokers Opposing SEBI’s Regulations In Algo Trading?
Glenmark Life Sciences IPO: Should You Subscribe? Strong Player In APIs With Focus On Contract Development and Manufacturing
Pharma Sector: Approvals Accorded Under PLI Scheme For Rs 348 Crore Investment In Drug Intermediates And APIs
Pharma Sector: Union Govt Approves Investments Of Rs 5,082 Crore Under PLI Scheme For APIs
Explained: Rs 15,000 Crore PLI Scheme For Pharmaceutical Companies That Aims To Achieve 'Atmanirbharta' In APIs And High-End Medicines
Indian Drug Makers Embrace 'Go Local' Mantra For APIs As They Seek To Reduce Dependence On China For Raw Materials
Govt To Set Up Three Bulk Drug Parks For Manufacturing Of APIs, To Invest Rs 14,300 Crore
Pharma Sector Seeks Urgent Clearance For APIs, Medical Devices Imported From China
One Each For Import And Export: How Over-Dependence On China And US Markets Blocks Indian Pharma’s Growth
